Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals EVP Liawatidewi Yakob reported a routine tax-related share disposition. On March 6, 2026, 1,144 shares of common stock were withheld at $19.34 per share to cover taxes on vesting restricted stock units, not as an open-market sale.
After this withholding, Yakob directly holds 89,345 shares of Amphastar common stock and indirectly holds 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, where she serves as trustee.
Amphastar Pharmaceuticals director and CEO Jack Y. Zhang reported routine tax-related share withholdings tied to restricted stock unit vesting. On March 6, 2026, a total of 10,850 shares of common stock were withheld to satisfy tax liabilities, rather than sold on the open market.
After these withholdings, Zhang holds 2,834,117 shares directly. Additional indirect holdings include 1,179,966 shares held of record by his spouse, Mary Z. Luo, and 6,827,679 shares held through Applied Physics and Chemistry Laboratories, Inc. and a related family trust.
Amphastar Pharmaceuticals insiders reported tax-related share withholdings tied to equity compensation, not open-market sales. CEO and Chief Scientific Officer Jack Y. Zhang had 5,769 shares of common stock withheld at $19.96 per share to satisfy tax liabilities from vesting restricted stock units, leaving 2,841,890 shares held directly.
Additional tax-withholding dispositions of 2,432 common shares at $19.96 per share were reported as indirectly owned, with 1,183,043 indirect shares remaining. Footnotes state that some securities are held of record by Mary Z. Luo and that 6,827,679 shares are held of record by Applied Physics and Chemistry Laboratories, Inc., which is owned by the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust.
Amphastar Pharmaceuticals senior executive Rong Zhou reported a small share disposition related to taxes, not an open-market sale. On the RSU vesting date, 1,124 shares of common stock were withheld at $19.96 per share to cover Zhou’s tax liability, leaving 136,919 shares held directly. In addition, 99,668 shares are held indirectly through the Zhou Family Trust, where Zhou serves as trustee, and 5,000 shares are held by Zhou’s spouse.
Amphastar Pharmaceuticals director and EVP Liawatidewi Yakob reported a tax-related share disposition. On March 4, 2026, 965 shares of common stock were withheld at $19.96 per share to satisfy her tax liability upon vesting of restricted stock units.
After this tax-withholding disposition, she directly held 90,489 common shares. She also indirectly held 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, which includes 545 shares acquired on May 31, 2025 under Amphastar’s 2014 Employee Stock Purchase Plan.
Amphastar Pharmaceuticals CFO William J. Peters had 1,744 shares of common stock withheld at $19.96 per share to cover taxes from vesting restricted stock units. After this tax-withholding disposition, he directly owns 123,786 shares, which include 545 shares acquired under the company’s 2014 Employee Stock Purchase Plan.
Amphastar Pharmaceuticals, Inc. reported new executive employment agreements for Jacob Liawatidewi and Rong Zhou effective March 3, 2026. Each agreement has a one-year term that automatically renews unless either party gives 90 days’ notice and can be terminated at any time with or without cause or good reason.
Liawatidewi will receive an annual base salary of $525,800 with a target cash bonus equal to 55% of base salary, while Zhou will receive $590,000 with a 53% target bonus. Both are eligible for equity incentives and standard company benefit plans.
On a qualifying termination, they may receive severance benefits subject to signing a release, with additional severance if it occurs within one year after a change in control. Upon any change in control during employment, 100% of their unvested equity awards will vest. Payments are also structured to address potential Section 280G excise taxes.
Amphastar Pharmaceuticals outlined two agreements with Chinese affiliates that it does not view as material to its financial results. Its subsidiary Amphastar Nanjing Pharmaceuticals signed a five-year supply agreement with Nanjing Letop Biotechnology, under which Letop will provide chemical intermediates. Amphastar can choose order volumes at its discretion and is not required to buy any minimum quantity. Payments will be made in Chinese yuan, and Amphastar retains ownership of shared confidential information.
Separately, Amphastar amended its contract research arrangement with Nanjing Hanxin Pharmaceutical Technology. The company will use Hanxin’s research cell banks to develop Master Cell Banks for product candidate AMP-105 instead of AMP-107. This change increases the total contract cost by about $0.6 million. Both Letop and Hanxin are majority-owned by family members of senior executives, and Amphastar’s Audit Committee reviewed and approved these related party transactions.
Amphastar Pharmaceuticals, Inc. reports its full-year 2025 results and outlines an expanded injectable, inhalation, and intranasal drug portfolio. Net revenues were $719.9 million in 2025 compared with $732.0 million in 2024, while net income declined to $98.1 million from $159.5 million.
The company’s largest products include BAQSIMI glucagon nasal powder, Primatene MIST, glucagon, epinephrine, and lidocaine. Amphastar completed the global transition of BAQSIMI distribution, launched FDA‑approved albuterol and iron sucrose products in 2024–2025, and gained approvals for teriparatide and Ipratropium Bromide HFA.
Amphastar is investing heavily in complex generics, biosimilar insulins and proprietary peptides, backed by 163 R&D employees and vertically integrated API facilities in the U.S., France, and China. At February 20, 2026, the company had 45,370,171 common shares outstanding, and key U.S. wholesalers McKesson, Cencora and Cardinal Health together represented most of its net revenues.
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2025 results showing modestly lower sales but a sharp drop in profit. Full-year net revenues were $719,887,000 versus $731,967,000 a year earlier, while GAAP net income declined to $98,094,000 from $159,519,000, and GAAP diluted EPS fell to $2.03 from $3.06.
Adjusted non-GAAP net income decreased to $156,618,000 from $200,806,000, with adjusted diluted EPS of $3.25 compared with $3.86. BAQSIMI® was a key growth driver, with 2025 product revenues of $185,358,000 up from $126,898,000, while glucagon and epinephrine products declined. Operating expenses rose, particularly general and administrative and research and development.
The company generated cash flow from operating activities of $156,100,000 for 2025 and ended the year with cash, cash equivalents, and short-term investments totaling $282,812,000. Amphastar highlighted recent FDA approvals for iron sucrose and teriparatide injections and expanded its proprietary pipeline with three novel peptides and a fully synthetic corticotropin compound targeting oncology, ophthalmology, and immunology markets.